Flozins to prevent contrast-related kidney injury after coronary angiography or PCI
FLOzins for pREveNtion of Contrast-inducEd Acute Kidney Injury (FLORENCE) Study
This project tests whether taking a flozin (empagliflozin or dapagliflozin), short-term or long-term, lowers the chance of contrast-induced acute kidney injury in patients having coronary angiography or PCI.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Collegium Medicum w Bydgoszczy Academic / other |
| Locations | 1 site (Bydgoszcz) |
| Trial ID | NCT07231939 on ClinicalTrials.gov |
What this trial studies
This is a retrospective, single-centre cohort/case-control analysis of all consecutive patients who underwent coronary angiography or PCI at Collegium Medicum w Bydgoszczy between 01.01.2020 and 30.09.2025. The final analysis includes only procedures with iodine contrast volume between 50 and 500 mL and patients with both pre- and post-procedure serum creatinine measurements. The study compares occurrence of contrast-induced AKI among patients with short-term versus long-term SGLT2 inhibitor (empagliflozin or dapagliflozin) use and will analyze baseline characteristics, contrast type and volume, and serial creatinine/eGFR changes at 24, 48, and 72 hours. Results will be combined with previously published studies in a planned meta-analysis.
Who should consider this trial
Good fit: Ideal candidates for inclusion are patients who underwent coronary angiography or PCI at Collegium Medicum w Bydgoszczy during the study period with documented contrast volume between 50 and 500 mL and available pre- and post-procedure serum creatinine measurements.
Not a fit: Patients with contrast volumes under 50 mL or over 500 mL, or with missing creatinine data, are excluded and therefore would not benefit from this analysis.
Why it matters
Potential benefit: If successful, using flozins around the time of contrast exposure could reduce cases of contrast-induced AKI and related short-term kidney complications in patients undergoing coronary angiography or PCI.
How similar studies have performed: Some observational and mechanistic studies suggest SGLT2 inhibitors have renal protective effects, but direct evidence specifically preventing contrast-induced AKI is limited and this study adds to a relatively small body of data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * all consecutive patients who underwent PCI or coronary angiography during the study period for whom the variables required for the analysis are available Exclusion Criteria: * unavailability of variables required for the analysis, volume * contrast agent volume \<50 mL or \>500 mL.
Where this trial is running
Bydgoszcz
- Collegium Medicum w Bydgoszczy — Bydgoszcz, Poland (Recruiting)
Study contacts
- Principal investigator: Jacek Kubica, Prof. — Collegium Medicum w Bydgoszczy
- Study coordinator: Piotr Niezgoda, MD, PhD
- Email: piotr.niezgoda1986@gmail.com
- Phone: +48525854023
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.